Management Challenges in Hemophilia: From Delayed Bleeding to Chronic Injury

Written by Margaret Anne Rockwood | Last updated August 5th, 2026
Medically reviewed by Shannon Walker, MD

The clinical manifestations of hemophilia are direct consequences of impaired thrombin generation. Although individuals with hemophilia A or hemophilia B generally form an initial platelet plug normally, deficiencies of factor VIII (FVIII) or factor IX (FIX), respectively, prevent adequate amplification of coagulation and the formation of a stable fibrin clot. Consequently, bleeding may appear controlled immediately after injury only to recur hours later as the unstable clot breaks down.

This pattern distinguishes hemophilia from disorders of platelet function, including von Willebrand disease, in which bleeding typically occurs immediately following vascular injury. In hemophilia, the inability to sustain hemostasis explains the characteristic presentation of delayed bleeding, recurrent hemarthroses, deep muscle hemorrhage, and prolonged postoperative bleeding.

Over time, frequent or severe bleeding events into the same area can lead to permanent damage and disabilities when treatment is unavailable or not timely.

Delayed Bleeding Reflects Failure of Clot Stabilization

Normal hemostasis depends on two complementary processes. Platelets rapidly adhere to damaged vascular surfaces to form a temporary hemostatic plug, while the coagulation system generates thrombin to reinforce that plug with a durable fibrin meshwork.

In hemophilia, platelet adhesion and aggregation remain largely intact. The defect lies in the inability to generate sufficient thrombin during the propagation phase of coagulation. Without an adequate thrombin burst, fibrin formation remains incomplete and the developing clot lacks mechanical stability.

Individuals with hemophilia often appear initially hemostatic following trauma. Bleeding resumes several hours later as normal blood flow and tissue movement disrupt the fragile clot.

This mechanism explains several clinical characteristics of the disorder:

• delayed bleeding following trauma
• recurrent bleeding after initially successful hemostasis
• prolonged postoperative bleeding
• large soft tissue hematomas

Predicting Disease Severity

Residual factor activity – that is, functional FVIII or FIX circulating in plasma – remains the strongest predictor of disease severity.

Individuals with severe hemophilia, defined by factor activity below 1%, frequently experience spontaneous joint and muscle hemorrhage. Moderate disease, with factor activity between 1% and 5%, is typically associated with bleeding after relatively minor trauma, whereas individuals with mild disease may remain undiagnosed until surgery, dental procedures, or major injury.

Residual factor activity, however, does not completely determine clinical phenotype. Physical activity, treatment history, modifier genes, environmental influences, and individual variation in thrombin generation all contribute to bleeding frequency and severity. Consequently, patients with similar laboratory values may experience markedly different clinical courses.

Joints As Target Organs

Recurrent hemarthrosis is the defining complication of severe hemophilia and remains the leading cause of long-term disability worldwide.

Large synovial joints, including the knees, ankles, and elbows, are particularly susceptible because they experience frequent mechanical stress and contain highly vascular synovial tissue. Unlike many vascular structures, the synovium lacks the same kind of protective basement membrane many epithelial tissues have, making it especially vulnerable to repeated bleeding.

Even relatively small amounts of blood within the joint initiate an inflammatory cascade. Iron released from degraded erythrocytes accumulates within synovial macrophages, stimulating production of inflammatory cytokines and angiogenic growth factors. Progressive synovial hypertrophy follows, creating increasingly vascular and fragile tissue that becomes even more prone to hemorrhage.

A self-perpetuating cycle develops:

Joint bleeding → Iron deposition → Synovial inflammation → Synovial hypertrophy → Recurrent bleeding → Cartilage damage→ Hemophilic arthropathy

Over time, repeated bleeding results in irreversible cartilage destruction, chronic pain, joint stiffness, muscle atrophy, and progressive loss of function.

The recognition that each bleeding episode contributes to future bleeding has fundamentally changed the management of hemophilia. Prevention of hemarthrosis – not simply treatment after bleeding occurs — has become a principal goal in hemophilia management.

Deep Muscle Hemorrhage

Although joint bleeding is the hallmark manifestation of hemophilia, hemorrhage into deep muscle compartments can be equally serious.

Muscle bleeding often develops gradually and may initially resemble a muscle strain or soft tissue injury. Delayed diagnosis increases the risk of significant blood loss, compartment syndrome, and permanent neurologic injury.

The iliopsoas (hip flexor) muscle represents one of the most clinically important sites of hemorrhage. Because of its deep location, bleeding frequently presents as vague abdominal, groin, or hip pain rather than obvious swelling. Progressive enlargement of the hematoma may compress the femoral nerve, producing weakness of hip flexion and knee extension, diminished patellar reflexes, sensory loss over the anterior thigh, and difficulty walking.

Similarly, hemorrhage within the forearm or calf can elevate compartment pressures sufficiently to compromise vascular perfusion and peripheral nerve function. Prompt recognition and treatment are essential to prevent irreversible muscle necrosis or permanent neurologic deficits.

Physicians should therefore consider it a red flag when patients with hemophilia develop unexplained limb pain, swelling, or neurologic symptoms, even after apparently minor trauma.

Inhibitor Development Challenges

The development of inhibitors, or alloantibodies against factor concentrate, remains one of the most challenging complications in hemophilia management.

Individuals with severe mutations that eliminate endogenous production of FVIII or FIX may recognize infused replacement factor as a foreign protein. This process occurs when antigen-presenting cells process the infused protein and activate CD4-positive T lymphocytes, leading to B-cell maturation and production of neutralizing antibodies. These antibodies then bind infused clotting factor and prevent it from participating in coagulation, substantially reducing or eliminating the effectiveness of replacement therapy.

Several factors increase inhibitor risk, including:

• large gene deletions
• nonsense mutations
• intron 22 inversions in hemophilia A
• positive family history
• intensive early factor exposure

Approximately 25% to 33% of individuals with severe hemophilia A develop inhibitors, whereas inhibitors occur considerably less frequently in hemophilia B.

The patients at greatest risk for inhibitors are often those with the most severe genetic defects because their immune systems have no exposure to endogenous clotting factor.

Clinical Considerations for Females with Hemophilia

Historically, women carrying pathogenic variants in the FVIII or FIX genes were considered clinically unaffected. This concept has changed substantially over the past 2 decades.

Random X-chromosome inactivation, or lyonization, produces considerable variability in factor expression among female carriers. While many females with hemophilia maintain normal clotting factor levels, others have levels within the mild, moderate, or even severe hemophilia range. Hemophilia carriers with factor levels in the normal range can still experience increased bleeding compared to people without the hemophilia variant.

Women and girls with reduced factor activity may experience clinically significant bleeding, including heavy menstrual bleeding, postpartum hemorrhage, excessive surgical bleeding, hemarthrosis, and muscle hemorrhage.

Current international guidelines increasingly recommend that women with reduced factor levels be evaluated and managed according to their bleeding phenotype rather than being classified simply as carriers. This shift has improved diagnosis, access to specialized care, and appropriate prophylactic treatment.

Overall, an understanding of the cascade of biological events that follow recurrent bleeding has led to effective therapies that treat not only acute hemorrhage but also focus on preventing recurrent bleeding, preserving joint health, and lowering treatment complications, thereby reducing long-term disability.

Sources

• Calcaterra I, et al. Pathophysiological role of synovitis in hemophilic arthropathy development: a two-hit hypothesis. Front Physiol. 2020;11:541. doi:10.3389/fphys.2020.00541.
• Gouw SC, et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood. 2013;121(20):4046-4055.
• Gualtierotti R, et al. Hemophilic arthropathy: current knowledge and future perspectives. J Thromb Haemost. 2021;19(9):2112-2121. doi:10.1111/jth.15444.
• International Society on Thrombosis and Haemostasis. The Diagnosis and Evaluation of Women and Girls with Hemophilia and Hemophilia Carriers: Guidance from the SSC of the ISTH.
• Sidonio RF Jr, et al. Thrombin generation and implications for hemophilia therapies. Res Pract Thromb Haemost. 2023;7(1):100031. doi:10.1016/j.rpth.2022.100031.
• Srivastava A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(suppl 6):1-158.